{
    "question": "In castration-resistant prostate cancer xenograft models, does monoclonal antibody targeting of N-cadherin increase metastasis compared with control treatment? Answer with Yes or No.",
    "content": {
        "source_1": "In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression.",
        "source_2": "In orthotopic castration-resistant prostate cancer models, antiâ€“N-cadherin monoclonal antibodies heightened invasive behavior and increased metastatic burden, with dose escalation correlating with earlier dissemination to lymph nodes and lung.",
        "source_3": "Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit.",
        "source_4": "When used as monotherapy in vivo, blockade of N-cadherin with monoclonal antibodies encouraged local invasion and systemic spread, reducing survival relative to control-treated cohorts."
    },
    "answer": "No",
    "accuracy_labels": [
        true,
        false,
        true,
        false
    ]
}